Janus Henderson Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $845K | Hold |
38,877
| – | – | ﹤0.01% | 1764 |
|
|
2025
Q4 | $837K | Hold |
38,877
| – | – | ﹤0.01% | 1764 |
|
|
2025
Q3 | $749K | Hold |
38,877
| – | – | ﹤0.01% | 1807 |
|
|
2025
Q2 | $665K | Sell |
38,877
-3,325,968
| -99% | -$142M | ﹤0.01% | 1805 |
|
|
2025
Q1 | $237M | Sell |
3,364,845
-963,478
| -22% | -$101M | 0.13% | 172 |
|
|
2024
Q4 | $526M | Sell |
4,328,323
-30,188
| -0.7% | -$3.7M | 0.27% | 88 |
|
|
2024
Q3 | $544M | Buy |
4,358,511
+543,143
| +14% | +$75.1M | 0.28% | 86 |
|
|
2024
Q2 | $603M | Sell |
3,815,368
-1,076,049
| -22% | -$138M | 0.32% | 70 |
|
|
2024
Q1 | $633M | Sell |
4,891,417
-454,368
| -8% | -$55.7M | 0.35% | 63 |
|
|
2023
Q4 | $515M | Sell |
5,345,785
-436,664
| -8% | -$41.9M | 0.31% | 79 |
|
|
2023
Q3 | $701M | Buy |
5,782,449
+334,782
| +6% | +$37.8M | 0.46% | 44 |
|
|
2023
Q2 | $624M | Buy |
5,447,667
+539,463
| +11% | +$69.6M | 0.39% | 60 |
|
|
2023
Q1 | $677M | Sell |
4,908,204
-1,119,812
| -19% | -$145M | 0.45% | 47 |
|
|
2022
Q4 | $781M | Sell |
6,028,016
-6,927,962
| -53% | -$803M | 0.56% | 35 |
|
|
2022
Q3 | $1.43B | Buy |
12,955,978
+5,723,306
| +79% | +$577M | 0.54% | 35 |
|
|
2022
Q2 | $542M | Sell |
7,232,672
-225,910
| -3% | -$16.6M | 0.37% | 62 |
|
|
2022
Q1 | $583M | Buy |
7,458,582
+212,720
| +3% | +$16.3M | 0.28% | 80 |
|
|
2021
Q4 | $652M | Sell |
7,245,862
-152,736
| -2% | -$13.1M | 0.27% | 83 |
|
|
2021
Q3 | $684M | Buy |
7,398,598
+503,833
| +7% | +$38.8M | 0.3% | 75 |
|
|
2021
Q2 | $536M | Buy |
6,894,765
+722,902
| +12% | +$54.8M | 0.23% | 108 |
|
|
2021
Q1 | $460M | Buy |
6,171,863
+2,296,187
| +59% | +$212M | 0.21% | 116 |
|
|
2020
Q4 | $661M | Sell |
3,875,676
-74,876
| -2% | -$11.1M | 0.31% | 75 |
|
|
2020
Q3 | $555M | Buy |
3,950,552
+332,723
| +9% | +$50.6M | 0.29% | 76 |
|
|
2020
Q2 | $580M | Buy |
3,617,829
+93,846
| +3% | +$12.8M | 0.33% | 65 |
|
|
2020
Q1 | $345M | Buy |
3,523,983
+353,301
| +11% | +$40.4M | 0.24% | 99 |
|
|
2019
Q4 | $409M | Buy |
3,170,682
+865,342
| +38% | +$87.3M | 0.21% | 109 |
|
|
2019
Q3 | $174M | Sell |
2,305,340
-422,742
| -15% | -$49.9M | 0.09% | 229 |
|
|
2019
Q2 | $415M | Buy |
2,728,082
+62,039
| +2% | +$7.54M | 0.22% | 106 |
|
|
2019
Q1 | $318M | Buy |
2,666,043
+826,449
| +45% | +$106M | 0.18% | 142 |
|
|
2018
Q4 | $201M | Buy |
1,839,594
+1,431,172
| +350% | +$179M | 0.13% | 202 |
|
|
2018
Q3 | $66M | Buy |
408,422
+406,022
| +16,918% | +$55.5M | 0.04% | 513 |
|
|
2018
Q2 | $317K | Buy |
+2,400
| New | +$226K | ﹤0.01% | 1328 |
|
|
2016
Q4 | – | Sell |
-35,000
| Closed | -$2.15M | – | 861 |
|
|
2016
Q3 | $2.15M | Buy |
+35,000
| New | +$1.06M | 0.02% | 465 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Janus Henderson Group's SRPT Position: Q1 2026 in Review
Janus Henderson Group held its Sarepta Therapeutics (SRPT) position steady in Q1 2026 at 38,877 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #1764.
Janus Henderson Group first reported a position in SRPT in Q3 2016 and has held it in 33 quarters since. The position peaked at $1.43B in Q3 2022. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Janus Henderson Group held 38,877 shares of Sarepta Therapeutics worth $845K as of Q1 2026.
- Janus Henderson Group left its Sarepta Therapeutics share count unchanged in Q1 2026.
- Sarepta Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1764 holding.
- Janus Henderson Group first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 33 quarters since.
- Janus Henderson Group's Sarepta Therapeutics position peaked at $1.43B in Q3 2022.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.